

The Maastricht Study

<https://neurodegenerationresearch.eu/survey/the-maastricht-study/>

Principal Investigators

Prof. Dr. C.D.A. Stehouwer

Institution

Maastricht University

Contact information of lead PI Country

Netherlands

Title of project or programme

The Maastricht Study

Source of funding information

EFRO OP Zuid, Maastricht University, MUMC+

Total sum awarded (Euro)

€ 16,000,000

Start date of award

01/04/2009

Total duration of award in years

7.0

The project/programme is most relevant to:

Alzheimer's disease & other dementias|Neurodegenerative disease in general

Keywords

Research Abstract

The Maastricht Study is an extensive phenotyping study that focuses on the etiology of type 2 diabetes (T2DM), its classic complications (cardiovascular disease, nephropathy, neuropathy and retinopathy), and its emerging comorbidities, including cognitive decline, depression, and respiratory, musculoskeletal, and gastrointestinal diseases. The study uses advanced state-of-the-art imaging techniques and extensive biobanking to determine health status in a population-based cohort of 10,000 individuals that is enriched with T2DM individuals. The Maastricht Study is expected to become one of the most extensive phenotyping studies in both the general

population and T2DM participants world-wide.

The aims of The Maastricht Study are to provide in-depth information on determinants of the development and progression of a) T2DM; b) its classic complications: cardiovascular disease, retinopathy, neuropathy and nephropathy; and c) its emerging comorbidities, such as cognitive decline, depression, and gastrointestinal, musculoskeletal and respiratory diseases. Thus, this study will specifically focus on possible mechanisms that may explain why T2DM accelerates the development and progression of classic complications and emerging comorbidities. This study will not only examine the development and progression of T2D and its classic complications and emerging comorbidities, but also their association with quality of life and use of health care resources.

Lay Summary

Further information available at:

Types:

Investments > €500k

Member States:

Netherlands

Diseases:

Alzheimer's disease & other dementias, Neurodegenerative disease in general

Years:

2016

Database Categories:

N/A

Database Tags:

N/A